Company intelligence / Profile preview

Kodiak Capital

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

Kodiak Sciences is advancing three late-phase candidates: tarcocimab (anti-VEGF ABC with consistent 6-month durability in Phase 3 studies for retinal vascular diseases), KSI-501 (Phase 3 for retinal vascular diseases), and KSI-101 (Phase 3 bispecific for MESI). Tarcocimab has three completed Phase 3 studies and two ongoing, showing favorable safety and durability.

Therapeutic areas: Ophthalmology
Modalities: Antibody Biopolymer ConjugateBispecific protein
Industry: Biotech

Beyond the preview

Go deeper on Kodiak Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kodiak Capital.

Explore the full profile